The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL

Flinn, IW, Hillmen, P orcid.org/0000-0001-5617-4403, Montillo, M et al. (22 more authors) (2018) The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL. Blood, 132 (23). pp. 2446-2455. ISSN 0006-4971

Abstract

Metadata

Authors/Creators:
  • Flinn, IW
  • Hillmen, P https://orcid.org/0000-0001-5617-4403
  • Montillo, M
  • Nagy, Z
  • Illés, Á
  • Etienne, G
  • Delgado, J
  • Kuss, BJ
  • Tam, CS
  • Gasztonyi, ZN
  • Offner, F
  • Lunin, S
  • Bosch, F
  • Davids, MS
  • Lamanna, N
  • Jaeger, U
  • Ghia, P
  • Cymbalista, F
  • Portell, CA
  • Skarbnik, AP
  • Cashen, AF
  • Weaver, DT
  • Kelly, VM
  • Turnbull, B
  • Stilgenbauer, S
Copyright, Publisher and Additional Information: © 2018 by The American Society of Hematology. This research was originally published in Blood. Flinn, IW, Hillmen, P , Montillo, M et al. (22 more authors) (2018) The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL. Blood, 132 (23). pp. 2446-2455. Uploaded in accordance with the publisher's self-archiving policy.
Dates:
  • Published: 6 December 2018
  • Accepted: 25 July 2018
  • Published (online): 4 October 2018
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > Institute of Molecular Medicine (LIMM) (Leeds) > Section of Experimental Haematology (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 08 Jan 2019 16:03
Last Modified: 04 Oct 2019 00:38
Status: Published
Publisher: American Society of Hematology
Identification Number: https://doi.org/10.1182/blood-2018-05-850461

Share / Export

Statistics